Scholarlink

Background <p>In small-biopsy carcinomas, tumor-origin assignment often relies on limited tissue, clinical-radiologic context, morphology, and immunohistochemistry. Although site-specific markers are widely used to support tumor-origin assignment, how often such assignment is supported by site-specific-marker–anchored IHC without CK7/CK20 dependence in context-rich, non-CUP/MUO small-biopsy cohorts has been less explicitly addressed. We therefore audited selected small-biopsy carcinomas with a single-site origin assigned at sign-out, to assess how often tumor-origin assignment was supported by site-specific-marker–anchored IHC without CK7/CK20 dependence.</p> Methods <p>We reviewed 154 consecutive small biopsies with IHC and analyzed the selected subset of carcinomas in which a single-site origin had been assigned at sign-out. We retrospectively audited the IHC markers used to support tumor-origin assignment, assessing IHC panel sufficiency, site-specific-marker–anchored support without CK7/CK20 dependence, and CK7/CK20 application, theoretical need, and incremental contribution.</p> Results <p>The selected analytic cohort included 60 carcinomas: 13 primary tumors, 43 metastases, and 4 malignancies of unknown origin submissions. Tumor origin was assigned as breast in 25% (15/60), colorectal in 20% (12/60), lung in 18% (11/60), and liver/hepatocellular carcinoma in 17% (10/60); other origins accounted for 20% (12/60). Overall diagnostic IHC sufficiency was achieved in 95% (57/60). Site-specific markers were applied in all cases. A site-specific-marker–anchored IHC approach was sufficient for tumor-origin assignment in 93% (56/60) of cases. CK7/CK20 was performed in 48% (29/60) of cases, was retrospectively considered theoretically needed in 12% (7/60), and was contributive to final tumor-origin assignment in 2% (1/60).</p> Conclusions <p>In this selected, context-rich, non-CUP/MUO small-biopsy cohort, tumor-origin assignment was supported in most cases (56/60, 93%) by site-specific-marker–anchored IHC without CK7/CK20 dependence; CK7/CK20 was selectively needed but showed limited incremental contribution beyond morphology, clinical/imaging context, and site-specific markers. This approach may have practical relevance for tissue-conscious IHC marker selection in small-biopsy workflows, alongside established pre-analytic standards. Further studies are warranted to confirm these findings, assess generalizability in broader biopsy settings, and evaluate diagnostic accuracy against external reference standards.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnosing carcinoma origin in ultrasound-guided needle biopsies: a context-driven approach anchored in site-specific immunohistochemical markers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月16日

查看全文
  • Gratiana Hermann,
  • Raluca Ghica,
  • Rares Buiga,
  • Iunia Cebotaru,
  • Daniela Coza,
  • Zeno Sparchez

摘要

Background

In small-biopsy carcinomas, tumor-origin assignment often relies on limited tissue, clinical-radiologic context, morphology, and immunohistochemistry. Although site-specific markers are widely used to support tumor-origin assignment, how often such assignment is supported by site-specific-marker–anchored IHC without CK7/CK20 dependence in context-rich, non-CUP/MUO small-biopsy cohorts has been less explicitly addressed. We therefore audited selected small-biopsy carcinomas with a single-site origin assigned at sign-out, to assess how often tumor-origin assignment was supported by site-specific-marker–anchored IHC without CK7/CK20 dependence.

Methods

We reviewed 154 consecutive small biopsies with IHC and analyzed the selected subset of carcinomas in which a single-site origin had been assigned at sign-out. We retrospectively audited the IHC markers used to support tumor-origin assignment, assessing IHC panel sufficiency, site-specific-marker–anchored support without CK7/CK20 dependence, and CK7/CK20 application, theoretical need, and incremental contribution.

Results

The selected analytic cohort included 60 carcinomas: 13 primary tumors, 43 metastases, and 4 malignancies of unknown origin submissions. Tumor origin was assigned as breast in 25% (15/60), colorectal in 20% (12/60), lung in 18% (11/60), and liver/hepatocellular carcinoma in 17% (10/60); other origins accounted for 20% (12/60). Overall diagnostic IHC sufficiency was achieved in 95% (57/60). Site-specific markers were applied in all cases. A site-specific-marker–anchored IHC approach was sufficient for tumor-origin assignment in 93% (56/60) of cases. CK7/CK20 was performed in 48% (29/60) of cases, was retrospectively considered theoretically needed in 12% (7/60), and was contributive to final tumor-origin assignment in 2% (1/60).

Conclusions

In this selected, context-rich, non-CUP/MUO small-biopsy cohort, tumor-origin assignment was supported in most cases (56/60, 93%) by site-specific-marker–anchored IHC without CK7/CK20 dependence; CK7/CK20 was selectively needed but showed limited incremental contribution beyond morphology, clinical/imaging context, and site-specific markers. This approach may have practical relevance for tissue-conscious IHC marker selection in small-biopsy workflows, alongside established pre-analytic standards. Further studies are warranted to confirm these findings, assess generalizability in broader biopsy settings, and evaluate diagnostic accuracy against external reference standards.